Search all trials

Find therapies in clinical trials near you – page 7

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Breast cancer metastatic

Not recruiting

Registered drugNo placebo

Study Comparing Olaparib and Pembrolizumab with Chemotherapy and Pembrolizumab for Patients with Advanced Triple-Negative Breast Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Breast cancer metastatic+2

Not recruiting

Registered drugNo placebo

Comparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Alpelisib

Contact Research Centre

Breast cancer metastatic

Not recruiting

Registered drugNo placebo

Study on Alpelisib and Fulvestrant or Ribociclib and Fulvestrant for Patients with HR+, HER2- Metastatic Breast Cancer with PIK3CA Mutations

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Alpelisib

Contact Research Centre

Breast cancer metastatic+1

Not recruiting

InvestigationalNo placebo

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Breast Cancer Resistant to Trastuzumab, Pertuzumab, and Taxane Treatment

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Trastuzumab Deruxtecan

Contact Research Centre

Breast cancer metastatic+1

Not recruiting

Registered drugNo placebo

Study on Cyclophosphamide for Patients with Advanced Breast Cancer with TP53 Mutations

Registered drugNo placebo

Norway

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide

Contact Research Centre

Breast cancer metastatic+1

Not recruiting

Registered drugNo placebo

Study of PF-07220060 and Letrozole for Postmenopausal Women with HR-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Letrozole

Contact Research Centre

Breast cancer metastatic+2

Not recruiting

Registered drugNo placebo

Study Comparing Oral Paclitaxel (DHP107) and IV Paclitaxel for Patients with Recurrent or Metastatic HER2 Negative Breast Cancer

Registered drugNo placebo

Hungary

Participants:18–64 years · 65+ years
Substances:Paclitaxel

Contact Research Centre

Breast cancer metastatic+2

Not recruiting

Registered drugNo placebo

Study of Durvalumab, Olaparib, and Fulvestrant for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer with Specific Genetic Alterations

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Durvalumab

Contact Research Centre

Breast cancer metastatic

Not recruiting

Registered drug

Study of fulvestrant and palbociclib combination for postmenopausal women with hormone receptor-positive metastatic breast cancer who completed 5 years of hormone therapy or have new metastatic disease

Registered drug

Ireland

Participants:18–64 years · 65+ years
Substances:Fulvestrant

Contact Research Centre

Breast cancer metastatic+5

Not recruiting

Registered drugNo placebo

Study on the Impact of Fluoroestradiol F-18 PET on Treatment for Patients with ER+ HER2- Metastatic Breast Cancer After First-Line Hormone Therapy Relapse

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Fluoroestradiol F-18

Contact Research Centre

Breast cancer metastatic+1

Not recruiting

Registered drugNo placebo

Study of Alpelisib, Trastuzumab, and Fulvestrant for Patients with PIK3CA Mutated HER2+ Advanced Breast Cancer Previously Treated with Trastuzumab

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Alpelisib

Contact Research Centre

Breast cancer metastatic+1

Not recruiting

Registered drugNo placebo

Study on Early Breast Cancer Treatment with Palbociclib, Tamoxifen, and Exemestane for Patients with Estrogen Receptor Positive Tumors

Registered drugNo placebo

Sweden

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Find therapies in clinical trials near you – page 7

84 trials match your criteria

Breast cancer metastatic

Study Comparing Olaparib and Pembrolizumab with Chemotherapy and Pembrolizumab for Patients with Advanced Triple-Negative Breast Cancer

Breast cancer metastatic+2

Comparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Breast cancer metastatic

Study on Alpelisib and Fulvestrant or Ribociclib and Fulvestrant for Patients with HR+, HER2- Metastatic Breast Cancer with PIK3CA Mutations

Breast cancer metastatic+1

Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Breast Cancer Resistant to Trastuzumab, Pertuzumab, and Taxane Treatment

Breast cancer metastatic+1

Study on Cyclophosphamide for Patients with Advanced Breast Cancer with TP53 Mutations

Breast cancer metastatic+1

Study of PF-07220060 and Letrozole for Postmenopausal Women with HR-Positive, HER2-Negative Breast Cancer

Breast cancer metastatic+2

Study Comparing Oral Paclitaxel (DHP107) and IV Paclitaxel for Patients with Recurrent or Metastatic HER2 Negative Breast Cancer

Breast cancer metastatic+2

Study of Durvalumab, Olaparib, and Fulvestrant for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer with Specific Genetic Alterations

Breast cancer metastatic

Study of fulvestrant and palbociclib combination for postmenopausal women with hormone receptor-positive metastatic breast cancer who completed 5 years of hormone therapy or have new metastatic disease

Breast cancer metastatic+5

Study on the Impact of Fluoroestradiol F-18 PET on Treatment for Patients with ER+ HER2- Metastatic Breast Cancer After First-Line Hormone Therapy Relapse

Breast cancer metastatic+1

Study of Alpelisib, Trastuzumab, and Fulvestrant for Patients with PIK3CA Mutated HER2+ Advanced Breast Cancer Previously Treated with Trastuzumab

Breast cancer metastatic+1

Study on Early Breast Cancer Treatment with Palbociclib, Tamoxifen, and Exemestane for Patients with Estrogen Receptor Positive Tumors

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.